Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,643 USD | +2,93% | -34,04% | +17,80% |
22/03 | Sangamo Therapeutics prijst $24 miljoen Geregistreerd Direct Aanbod | MT |
14/03 | Sangamo Therapeutics duwt neurologieprogramma's richting klinische ontwikkeling, zegt Wedbush | MT |
Omzet 2024 * | 36,94 mln. 34,23 mln. | Omzet 2025 * | 64,14 mln. 59,43 mln. | Marktkapitalisatie | 127 mln. 118 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -109 mln. -101 mln. | Nettowinst (verlies) 2025 * | -82 mln. -75,98 mln. | EV/omzet 2024 * | 4,55 x |
Nettoschuld 2024 * | 40,79 mln. 37,79 mln. | Nettoschuld 2025 * | 129 mln. 120 mln. | EV/omzet 2025 * | 4 x |
K/w-verhouding 2024 * |
-1,25
x | K/w-verhouding 2025 * |
-2,03
x | Werknemers | 405 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,55% |
Recentste transcriptie over Sangamo Therapeutics, Inc.
1 dag | +2,93% | ||
1 week | -34,04% | ||
Lopende maand | -44,83% | ||
1 maand | -40,19% | ||
3 maanden | +6,84% | ||
6 maanden | +10,86% | ||
Lopend jaar | +17,80% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Alexander Macrae
CEO | Chief Executive Officer | 61 | 01-06-16 |
Director of Finance/CFO | 46 | 01-03-19 | |
Gregory Davis
CTO | Chief Tech/Sci/R&D Officer | - | 01-05-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Peg Horn
BRD | Director/Board Member | 61 | 15-12-22 |
James Meyers
BRD | Director/Board Member | 58 | 22-11-19 |
H. Parker
CHM | Chairman | 68 | 19-06-14 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
3.66% | 2 M€ | -25,75% | ||
0.49% | 17 M€ | -0,46% |
Datum | Koers | Variatie | Volume |
---|---|---|---|
28-03-24 | 0,64 | +2,45% | 611 636 |
27-03-24 | 0,6247 | +3,53% | 2 650 625 |
26-03-24 | 0,6034 | -5,97% | 2 282 595 |
25-03-24 | 0,6417 | -8,72% | 2 855 904 |
22-03-24 | 0,703 | -27,55% | 6 598 653 |
uitgestelde koers Nasdaq, 28 maart 2024 om 19:22 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,80% | 127 mln. | |
+2,57% | 108 mld. | |
+9,67% | 104 mld. | |
+6,58% | 23,66 mld. | |
-12,38% | 22,1 mld. | |
-3,29% | 19,71 mld. | |
-35,36% | 18,2 mld. | |
-13,22% | 16,19 mld. | |
+4,14% | 13,72 mld. | |
+34,31% | 12,22 mld. |